Clinical trials: Biliary Tract Cancer
Gallbladder Carcinoma
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Mesylate Combined With SOX Regimen and SOX Regimen for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
- Trial name
- NCT03702491
- Testing
- Apatinib, Tegafur
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Biliary Tract Cancer
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract…
- Trial name
- NCT05254847
- Testing
- Capecitabine combined with lenvatinib and tislelizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Pancreatic Neoplasms, Biliary Tract Neoplasms
Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy
The purpose of this study is to determine whether duct-to-mucosa is better than invagination in pancreaticojejunostomy after pancreaticoduodenectomy.
- Trial name
- NCT01695447
- Testing
- duct-to-mucosa, invagination, Internal stent
- Where
- China
- Volunteers
- 100 people
- Sponsor
- TingBo Liang
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Biliary Tract Carcinoma, Gallbladder Carcinoma
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
This is a phase II study (the second stage of testing a new drug or new drug combinations) to see how useful two different schedules of study drug selumetinib with cisplatin and gemcitabine are compared to cisplatin and…
- Trial name
- NCT02151084
- Testing
- Selumetinib, Cisplatin, Gemcitabine
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- University Health Network, Toronto
Cholangiocarcinoma, Gall Bladder Carcinoma
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
To determine the efficacy in terms of objective response rate (ORR) of the combination of durvalumab and tremelimumab in addition with gemcitabine or in addition with gemcitabine and cisplatin in treatment-naïve patients with…
- Conditions
- Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable
- Trial name
- IMMUCHEC (NCT03473574)
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- AIO-Studien-gGmbH
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00363584
- Testing
- capecitabine, clinical observation, adjuvant therapy
- Where
- 46 sites in United Kingdom
- Volunteers
- 360 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Biliary Tract Cancer
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
A Phase Ⅱ, open-label, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer.
- Trial name
- NCT05056116
- Testing
- Surufatinib Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Biliary Tract Neoplasms, Gastric Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and…
- Conditions
- Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- VISIONARY (NCT04584008)
- Testing
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Other Therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Congenital Biliary Dilation
Treatment Strategy for Adult Congenital Biliary Dilation
The management of congenital biliary dilations (CBDs), including choledochal cysts, represents one of the most challenging areas in hepatobiliary surgery due to their potential implications for long-term morbidity and malignant…
- Trial name
- NCT07336576
- Testing
- hepatectomy、liver transplantation、hepaticojejunostomy
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Ampullary Cancer, Bile Duct Cancer
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
The incidence rate and mortality rate of periampullary cancer at home and abroad both show an increasing trend, seriously affecting the health level of the people.
- Conditions
- Ampullary Cancer, Bile Duct Cancer, Pancreas Cancer, Duodenum Cancer
- Trial name
- NCT06076252
- Testing
- Modified Blumgart Anastomosis in LPD, conventional Blumgart anastomosis in LPD
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Biliary Tract Neoplasms
Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
As a result of our previous NCRN study (ABC-02) cisplatin and gemcitabine (CisGem) is likely to become the international standard of care for patients with advanced biliary tract cancer (submitted: ASCO 2009).
- Trial name
- ABC-03 (NCT00939848)
- Testing
- gemcitabine, cisplatin, cediranib
- Where
- 2 sites in United Kingdom
- Volunteers
- 124 people
- Sponsor
- University College, London
Gallbladder Carcinoma
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
- Trial name
- NCT04183712
- Testing
- gemcitabine and oxaliplatin., Afatinib
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer.
- Trial name
- NCT05985707
- Testing
- KN026, KN046, XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Pancreatic Cancer, Biliary Cancer
Preoperative Nutritional Support in Malnutritional Cancer Patients
Malnutrition patients are known to have more postoperative complications and mortality. And most of hepatobiliary-pancreatic cancer surgeries accompany high postoperative morbidity and mortality rate.
- Conditions
- Pancreatic Cancer, Biliary Cancer, Malnutrition
- Trial name
- NCT02626195
- Testing
- nutritional support program
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Advanced Biliary Tract Cancer
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
The objective of this study is to evaluate the efficacy and safety of oncolytic virotherapy combined with Tislelizumab plus lenvatinib in patients with advanced biliary tract cancer (BTC).
- Trial name
- OPTIONS-05 (NCT05823987)
- Testing
- H101, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University